Objectives: We studied the performance of aminoglycosides in treating bloodstream infections (BSIs) of urinary source caused by ESBL-producing Enterobacteriaceae (ESBL-EB).
Methods: In a retrospective study of 193 patients with a clinical diagnosis of urinary tract infection, pyelonephritis or urosepsis and blood and urine cultures positive for ESBL-EB, patients were grouped according to whether they were treated with an aminoglycoside, a carbapenem or piperacillin/tazobactam. Multivariate analysis was used to define risk factors for mortality with inverse probability of treatment weighting used to minimize confounding. The primary efficacy outcome was 30 day mortality. The primary safety outcome was acute kidney injury (AKI) at 14 days.
Results: Mean age was 79.3 years. Dementia, chronic kidney disease and the presence of a urinary catheter were common. Thirty-two (16.6%) patients died and risk factors for mortality included age, high Charlson score, presentation with severe sepsis/septic shock and infection with bacteria other than Escherichia coli. Aminoglycosides were non-inferior compared with other antibiotics regarding 30 day mortality [13.0% versus 21.2%, respectively; adjusted risk difference=10.29% (-0.82% to 21.41%)], but did not reach non-inferiority for bacteriuria recurrence [48.9% versus 44.7%, respectively; adjusted risk difference=-8.72% (-30.87% to 13.43%)]. AKI developed at a similar rate in both treatment groups: 12.0% versus 10.6%, respectively [OR=1.14 (0.46-2.81)]. Aminoglycosides were more efficacious in E. coli infections compared with other ESBL-EB.
Conclusions: We demonstrated the efficacy and safety of aminoglycosides in treating BSI of urinary source caused by ESBL-EB. This carbapenem-sparing approach can assist in avoiding excessive carbapenem use without compromising outcomes.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: email@example.com.
Risk Factors and Outcomes in Non-Transplant Patients With Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Bacteremia: A Retrospective Study From 2013 to 2016T Xiao et al. Antimicrob Resist Infect Control 8, 144. PMID 31467670.Prior use of cephalosporin or BLBLI combination antibiotics increased the risk ratio for ESBL-producing E. coli infection. Hypoproteinemia and severe diseas …
Clinical Outcomes of Elderly Patients With Bloodstream Infections Due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in an Italian Internal Medicine WardS Meini et al. Eur J Intern Med 48, 50-56. PMID 29089174.Carbapenem-sparing regimens (e.g. piperacillin-tazobactam alone or with an aminoglycoside) could be empirically safely used in elderly patients at high risk of ESBL-EB BS …
Empiric Piperacillin-Tazobactam Versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing EnterobacteriaceaeTM Ng et al. PLoS One 11 (4), e0153696. PMID 27104951.Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae are a common cause of bacteraemia in endemic countries and may be associated with high mortality; car …
An Update on the Management of Urinary Tract Infections in the Era of Antimicrobial ResistanceMS Bader et al. Postgrad Med 129 (2), 242-258. PMID 27712137. - ReviewUrinary tract infections (UTIs) caused by antibiotic-resistant Gram-negative bacteria are a growing concern due to limited therapeutic options. Gram-negative bacteria, sp …
Epidemiology and Impact of Bloodstream Infections Among Kidney Transplant Recipients: A Retrospective Single-Center ExperienceAM Shendi et al. Transpl Infect Dis 20 (1). PMID 29151282. - ReviewUrinary tract infection remains the commonest source of systemic infection among kidney transplant recipients and resistance to commonly used frontline antibiotics is com …